CT/NG检测市场按技术、产品类型、最终用户和检测类型划分－2025-2032年全球预测

预计到 2032 年，CT/NG 检测市场将成长至 31.6 亿美元，复合年增长率为 7.70%。

关键市场统计数据
基准年 2024	17.4亿美元
预计年份：2025年	18.7亿美元
预测年份 2032	31.6亿美元
复合年增长率 (%)	7.70%

为披衣菌感染和淋病检测诊断技术的发展指明清晰的策略方向，为经营团队技术结构、临床效用和采购影响。

本执行摘要对当前披衣菌感染和淋病检测的临床诊断趋势进行了全面的分析回顾，重点关注正在重塑临床实践的技术趋势、相关人员的行为以及营运压力。本文将诊断创新置于更广泛的医疗服务背景下进行探讨，指出诊断准确性、结果出具时间以及与治疗路径的整合日益影响着临床效用和采购决策。因此，本报告旨在使高阶主管了解影响诊断应用的关键转折点，并重点阐述临床营运和商业策略的实际考量。

重点，引言部分从多个观点审视了诊断领域：包括培养、杂合反应、免疫检测和核酸增幅检查技术能力；耗材、仪器和软体等产品和服务；以及学术研究机构、诊所、诊断实验室和医院等终端使用者的需求。在建构了这个结构化观点之后，后续章节将技术细节转化为对临床实务、供应链和法规遵循的策略意义。因此，读者将能够清楚地了解诊断方法与实际应用场景之间的联繫，从而能够更明智地确定投资和伙伴关係机会的优先顺序。

分子诊断加速、多重检测和分散式诊断将如何全面重塑衣原体/淋球菌检测的临床工作流程和筹资策略

分子诊断技术的加速应用、多重检测需求的不断增长以及对分散式检查模式的重视（即在更靠近诊疗点的位置进行高灵敏度检测），正在推动诊断领域的变革性变化。核酸增幅检查已从集中式实验室转向快速工作流程，这得益于等温扩增技术的进步和聚合酵素链锁反应平台稳定性的提升。这促使临床路径优先考虑那些既能加快出结果速度又能确保诊断准确性的检测方法，从而促使医院和诊所重新思考其实验室流程和分诊通讯协定。

同时，软体和资料管理工具的融合正在改变检测结果的解读和应用方式。自动化分析仪和互联设备提高了检测通量，并减少了人为错误。这项技术变革与不断变化的监管要求和品管框架相互作用，迫使製造商和实验室管理人员加强对检验、可追溯性和互通性的投入。此外，耗材创新、检测设计和仪器功能正在推动更实用的双重检测策略，从而能够在单一工作流程中同时检测披衣菌感染衣原体和淋病奈瑟菌。这些趋势正在推动临床、商业和营运职能部门进行策略性重新评估，需要研发、生产和客户支援团队之间的协调应对。

评估2025年美国关税对诊断产品供应链、采购惯例以及製造商在地化决策的影响，并分析其对营运的影响。

美国2025年实施的关税调整的累积影响正对诊断供应链、采购决策和製造商成本结构产生重大影响。进口试剂、设备和某些零件的关税调整增加了到岸成本，促使买卖双方重新评估筹资策略并探索替代物流模式。为此，许多相关人员正在加快近岸外包的讨论，实现供应商组合多元化，并重新评估库存缓衝，以维持检测服务的连续性并应对价格的暂时波动。

这些贸易政策的变化也影响产品蓝图和投资时间表。先前依赖低成本国际供应链的製造商被迫考虑本地生产，并与经销商协商新的商业条款。因此，采购部门优先考虑提高合约透明度，并签署长期供应协议，以确保关键耗材和PCR设备的稳定供应。从临床角度来看，关税凸显了弹性供应计画的重要性。诊断实验室和医院网路正致力于寻找检验的替代检测方法和冗余设备平台，以降低试剂供应限制和进口成本波动带来的营运风险。

综合細項分析揭示了技术差异、产品组合、最终用户需求和测试类型如何融合，从而驱动诊断选择和实施策略。

关键的细分洞察揭示了技术选择、产品形式、最终用户需求和检测类型如何相互交织，从而影响技术采纳路径和采购优先顺序。技术细分涵盖培养方法、杂合反应检测、免疫检测和核酸增幅检查。在核酸增幅检查中，相关人员区分等温扩增和聚合酵素链锁反应。等温扩增方法包括恒温环型核酸扩增(LAMP) 和转录媒介增幅(TMA)，而聚合酵素链锁反应则包括嵌套 PCR 和即时PCR等变体，每种方法在性能、通量和工作流程方面各有优劣。这些技术差异决定了临床适应症标准和实验室整合要求，在选择诊断解决方案时，应在评估通讯协定的製定中加以体现。

产品类型细分包括耗材和试剂、仪器以及软体和服务。耗材和试剂包括品管样品、套件以及探针和引子。仪器涵盖从自动化系统到杂合反应分析仪和PCR仪等各种类型。软体和服务则着重于资料管理、连结性和生命週期支援。最终用户细分包括学术研究机构、诊所、诊断实验室和医院。每个机构都有其独特的通量需求、认证限制和采购週期，这些都会影响产品选择。检测类型细分重点在于披衣菌感染检测、双重检测和淋病检测。双重检测尤其因其操作效率高且在寻求整合诊断路径的环境中具有临床价值而日益普及。这些细分观点有助于根据目标使用者和应用程式场景系统地确定投资、检验和商业化工作的优先顺序。

不同地区在诊断方法应用、监管复杂性和采购行为方面的差异（美洲、欧洲、中东和非洲、亚太地区）需要针对每个地区制定量身定制的商业性策略。

美洲、欧洲、中东和非洲地区以及亚太地区的法规环境、临床应用和供应链结构各不相同，导致製造商和采购商的优先事项也存在差异。在美洲，对快速、灵敏的分子诊断的需求以及完善的检测网络推动了核酸扩增方法和自动化系统的广泛应用，但采购团队仍然专注于成本和供应连续性问题。同时，在欧洲、中东和非洲地区，不同的管理体制和医疗基础设施造成了不同的市场准入考量，因此需要製定适应性强的市场进入策略和灵活的检验方案，以适应不同的认证途径。

亚太地区的特点是部分都市区创新技术的快速普及以及各市场临床基础设施的显着差异，这凸显了模组化仪器平台和可客製化试剂组的价值。在所有地区，随着医疗系统优先考虑简化患者就诊流程和减少追踪次数，双重检测和就地检验方案的重要性日益凸显。此外，区域采购政策、公共卫生筛检计画和报销环境持续影响终端使用者的购买行为，这凸显了客製化商业模式、在地化伙伴关係以及监管合规准备对于在不同地区取得成功的重要性。

竞争分析重点在于检测创新、仪器自动化、数位化连接和供应链韧性，这些因素决定了诊断公司的成功。

诊断生态系统中的主要企业正在积极寻求差异化策略，涵盖检测创新、设备自动化和数位化连接等领域，同时应对监管审查和供应链限制。成功的企业将强大的研发开发平臺（专注于高灵敏度核酸扩增和多重检测技术开发）与可扩展的耗材和试剂生产能力相结合。同时，对自动化平台、杂合反应分析仪和PCR仪的投资，能够简化工作流程并减少人工操作时间，仍是客户提升营运效率的关键差异化因素。

为了加快产品上市速度并拓展分销网络，策略联盟和OEM协议正变得越来越普遍。那些透过软体和服务增强产品线，从而实现结果管理、分析和合规支援的公司，往往能够更深入地融入医疗保健系统。此外，那些拥有灵活的供应模式和透明的品质系统的公司，更有能力赢得大型机构客户的信任，并在采购竞标中脱颖而出。总而言之，创新、规模、互联互通和供应韧性这四项能力，是当今CT/NG诊断市场竞争优势的核心要素。

给领导者的具体策略建议：整合研发、製造弹性、互通性和客製化的商业模式，以加速推广应用并降低中断风险。

产业领导者应优先考虑整合技术投资、供应链韧性和以客户为中心的支援的策略，以掌握临床和商业性机会。首先，推动研发，开发稳健的核酸增幅检查以及多重和双联检测技术，将满足临床对快速、准确和一体化诊断​​的需求，同时提升临床工作流程的效率。其次，透过近岸外包、契约製造伙伴关係或多元化的供应商网路来增强生产弹性，将降低贸易政策变化带来的风险，并减少单一来源供应中断的影响。

此外，企业应提高仪器和软体的互通性，以降低使用不同分析仪器的实验室和诊所的采用障碍。对监管资讯和快速检验流程的策略性投资将有助于企业进入不同地区的市场。此外，针对学术研究机构、诊所、诊断实验室和医院等各自独特的采购週期，开发客製化的商业模式，将有助于提高合约中标率和客户维繫。最后，促进与公共卫生计画和临床网路的倡议，可以增强信誉并加速产品推广，尤其对于那些能够在筛检和治疗流程中即时产生实际效益的双重检测解决方案而言更是如此。

严谨的多方法研究框架，结合了关键相关利益者访谈、技术检测评估和二手证据，提供了检验且可操作的诊断见解。

我们的研究途径采用了多方法框架，结合了关键相关人员对话、技术检测审查和二手文献综合，以提供可靠的实用见解。主要研究包括对实验室技术人员、临床决策者、采购人员和监管专家进行结构化访谈，以了解操作限制、检验要求和实施驱动因素。这些对话辅以对检测设计、仪器规格和工作流程整合的技术审查，以比较不同应用场景下的性能特征和适用性。

二次研究利用已发布的监管文件、临床指南和同行评审文献，对核酸扩增方法、杂合反应检测和免疫检测的临床效用和证据标准进行了背景分析。资料综合采用多资讯来源三角验证法，以检验主题发现并识别一致的操作模式。品质保证措施包括对访谈结果进行交叉检验、系统记录资料来源以及内部同行评审，以确保分析的严谨性。这种多层次的调查方法确保了结论和建议是基于真实的临床实践，同时兼顾了监管和供应链的实际情况。

本文综合分析了诊断趋势，阐述了技术融合、营运韧性和目标商业化如何协同作用，才能维持其应用并产生临床影响。

总之，随着分子技术、仪器自动化和数据整合技术的融合，衣原体/淋巴瘤诊断领域正经历着积极的变革时期，这些技术共同推动了临床路径的改进和营运效率的提升。双重检测方法的兴起和分散式检查可行性的不断提高，正在重塑施行地点；同时，关税带来的供应链压力凸显了生产灵活性和采购流程透明度的必要性。综上所述，这些趋势表明，未来要实现永续应用，技术能力必须与稳健的营运实务和有针对性的商业性合作相辅相成。

决策者面临的挑战显而易见：产品开发和商业化计画必须与最终用户的实际限制、区域法规环境和供应链实际情况相符。这将使机构能够加快临床应用，加强客户关係，并降低营运风险。未来发展需要协调投资于检测创新、设备互通性和供应链网路设计，同时制定积极的监管计划和客製化的市场推广策略，以满足学术机构、临床实验室、诊所和医院的多元化需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 照护现场分子诊断技术的出现缩短了CT/NG检测的周转时间
• 整合数位健康平台，简化CT/NG检查预约与病患追踪流程
• 采用包含披衣菌感染/淋病双球菌检测和其他性行为感染传染病检测项目的多综合征检测组合，以提高诊断准确性
• 随着远端医疗的普及，对用于 CT/NG筛检的家用自采集套件的需求日益增长。
• 抗菌药物抗药性监测对淋球菌核酸扩增检测技术开发及市场趋势的影响
• 监管过渡：下一代披衣菌感染/淋病筛检测试获得FDA核准
• 利用CRISPR基因编辑技术提升披衣菌感染和淋病检测流程灵敏度的新方法

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第 8 章：按技术分類的 CT/NG 检测市场

• 培养方法
• 杂合反应方法
• 免疫检测
• 核酸增幅检查
  • 等温扩增
    • 恒温环型核酸扩增
    • 转录媒介增幅
  • 聚合酵素链锁反应
    • 嵌套聚合酵素链锁反应
    • 即时聚合酵素链锁反应

9. CT/NG检测市场依产品类型划分

• 耗材和试剂
  • 控製材料
  • 套件
  • 探针和引子
• 装置
  • 自动化系统
  • 杂合反应分析设备
  • 聚合酵素链锁反应装置
• 软体和服务

第 10 章：最终用户 CT/NG 检测市场

• 学术研究机构
• 诊所
• 诊断实验室
• 医院

第 11 章：按测试类型分類的 CT/NG 测试市场

• 披衣菌感染检测
• 双重检查
• 淋病检测

第十二章：按地区分類的 CT/NG 检测市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 13 章：CT/NG 检测市场（按群体）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第14章：按国家分類的CT/NG检测市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Danaher Corporation
  • bioMerieux SA
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • PerkinElmer, Inc.

The CT/NG Testing Market is projected to grow by USD 3.16 billion at a CAGR of 7.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.74 billion
Estimated Year [2025]	USD 1.87 billion
Forecast Year [2032]	USD 3.16 billion
CAGR (%)	7.70%

A clear and strategic orientation to diagnostic evolution for chlamydia and gonorrhea testing that frames technology, clinical utility, and procurement implications for executives

This executive summary introduces a comprehensive analytical review of current clinical diagnostic dynamics for Chlamydia and Gonorrhea testing, emphasizing technological trajectories, stakeholder behavior, and operational pressures that are reshaping clinical practice. The narrative situates diagnostic innovation within the broader context of healthcare delivery, where diagnostic accuracy, turnaround time and integration with care pathways increasingly determine clinical utility and procurement decisions. As such, this document seeks to orient senior leaders to the critical inflection points influencing diagnostic adoption while clarifying practical considerations for clinical operations and commercial strategy.

Importantly, the introduction frames the diagnostic landscape through multiple lenses: technological capability across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; product and service composition including consumables, instruments and software; as well as end-user requirements spanning academic and research institutes, clinics, diagnostic laboratories and hospitals. By establishing this structured perspective, subsequent sections translate technical detail into strategic implications for clinical practice, supply chains and regulatory engagement. As a result, readers should expect clear linkages between diagnostic modalities and real-world deployment scenarios, enabling informed prioritization of investments and partnership opportunities.

How molecular acceleration, multiplex testing, and decentralized diagnostics are collectively reshaping clinical workflows and procurement strategies in CT/NG testing

Transformative shifts in the diagnostic landscape are driven by accelerating molecular adoption, rising demand for multiplexing, and a stronger emphasis on decentralized testing models that bring high-sensitivity assays closer to point-of-care settings. Nucleic acid amplification tests have moved from centralized labs into rapid workflows, supported by advances in isothermal methods and increasingly robust polymerase chain reaction platforms. Consequently, clinical pathways are adapting to favor tests that reduce time-to-result while preserving diagnostic fidelity, prompting health systems and clinics to reassess laboratory routing and triage protocols.

Meanwhile, integration of software and data management tools is changing how test results are interpreted and acted upon, with automated analyzers and connected instruments enhancing throughput and reducing manual errors. This technological shift interacts with evolving regulatory expectations and quality frameworks, requiring manufacturers and laboratory managers to invest in validation, traceability and interoperability. In parallel, the convergence of consumables innovation, assay design and instrument capability is unlocking more practical dual testing strategies, enabling simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in a single workflow. Together, these dynamics are driving strategic reassessments across clinical, commercial and operational functions, and they demand coordinated responses across R&D, manufacturing and customer support teams.

Assessment of the 2025 United States tariff effects on diagnostic supply chains, procurement practices, and manufacturer localization decisions with operational implications

Cumulative impacts of tariff changes implemented in the United States in 2025 have material consequences for the diagnostic supply chain, procurement decision-making and manufacturer cost structures. Tariff adjustments on imported reagents, instruments and certain components have elevated landed costs, prompting purchasers and suppliers alike to reassess sourcing strategies and to explore alternative logistics models. In response, many stakeholders have accelerated nearshoring discussions, diversified supplier portfolios and re-evaluated inventory buffers to preserve continuity of testing services and to manage episodic price volatility.

These trade policy shifts also influence product roadmaps and investment timelines. Manufacturers that previously relied on low-cost international supply chains are now compelled to examine localized manufacturing or to negotiate revised commercial terms with distributors. As a result, procurement teams are prioritizing greater contractual transparency and longer-term supply agreements to stabilize access to critical consumables and PCR instruments. From a clinical perspective, the tariffs underscore the importance of resilient supply planning: diagnostic laboratories and hospital networks are increasingly focused on identifying validated alternative assays and redundant instrument platforms to mitigate the operational risks associated with constrained reagent availability and fluctuating import costs.

Integrated segmentation analysis reveals how technology variants, product composition, end-user requirements, and test types converge to drive diagnostic selection and implementation strategies

Key segmentation insights illuminate how technology choices, product formats, end-user needs and test types intersect to shape adoption pathways and procurement priorities. Technology segmentation ranges across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; within nucleic acid amplification, stakeholders differentiate between isothermal amplification and polymerase chain reaction, while isothermal approaches encompass loop mediated isothermal amplification and transcription mediated amplification and polymerase chain reaction may involve nested PCR and real time PCR variants, each offering distinct performance, throughput and workflow trade-offs. These technological distinctions drive clinical suitability criteria and laboratory integration requirements and should inform evaluation protocols when selecting diagnostic solutions.

Product type segmentation separates consumables and reagents, instruments, and software and services; consumables and reagents include control materials, kits, and probes and primers, while instruments range from automated systems to hybridization analyzers and PCR instruments, and software and services address data management, connectivity and lifecycle support. End-user segmentation identifies academic and research institutes, clinics, diagnostic laboratories and hospitals, each of which has unique throughput demands, accreditation constraints and purchasing cadences that influence product selection. Test type segmentation highlights chlamydia tests, dual tests and gonorrhea tests, with dual tests gaining traction for their operational efficiency and clinical value in settings seeking consolidated diagnostic pathways. Taken together, these segmentation lenses provide a structured way to prioritize investment, validation and commercialization efforts according to target users and use cases.

Regional differentiation in diagnostic adoption, regulatory complexity, and procurement behavior across Americas, Europe, Middle East & Africa, and Asia-Pacific requiring tailored commercial approaches

Regional dynamics vary in regulatory context, clinical adoption, and supply chain architecture across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing differentiated priorities for manufacturers and purchasers. In the Americas, demand for rapid, high-sensitivity molecular diagnostics and established laboratory networks supports broad adoption of nucleic acid amplification and automated systems, yet procurement teams remain attentive to cost and supply continuity concerns. Conversely, in Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare infrastructure create a mosaic of market entry considerations, necessitating adaptive go-to-market strategies and flexible validation packages that accommodate divergent accreditation pathways.

The Asia-Pacific region exemplifies rapid innovation adoption in certain urban centers alongside significant variability in clinical infrastructure across markets, which amplifies the value of modular instrument platforms and adaptable reagent kits. Across all regions, dual testing modalities and point-of-care options are becoming increasingly relevant as health systems prioritize streamlined patient pathways and reduced follow-up visits. Furthermore, regional procurement policies, public health screening programs and reimbursement environments continue to shape end-user purchasing behavior, underscoring the need for tailored commercial models, local partnerships and regulatory preparedness to succeed across diverse geographies.

Competitive capabilities analysis highlighting assay innovation, instrument automation, digital connectivity, and supply resilience that define success for diagnostic companies

Leading companies in the diagnostic ecosystem are advancing differentiated strategies across assay innovation, instrument automation, and digital connectivity, while simultaneously navigating regulatory scrutiny and supply chain constraints. Successful players are those that pair robust R&D pipelines-focused on high-sensitivity nucleic acid amplification and multiplex assay development-with scalable manufacturing capabilities for consumables and reagents. In parallel, investment in automated platforms, hybridization analyzers and PCR instruments that simplify workflow adoption and reduce hands-on time remains a principal differentiator for customers seeking operational efficiency.

Strategic partnerships and OEM arrangements are increasingly common as firms seek to accelerate time-to-market and broaden distribution reach. Companies that augment product offerings with software and services that enable result management, analytics and compliance support tend to achieve deeper integration within health systems. Additionally, those that maintain flexible supply models and transparent quality systems are better positioned to reassure large institutional customers and to respond to procurement tenders. Taken together, these capabilities-innovation, scale, connectivity and supply resilience-constitute the core attributes that define competitive advantage in the current CT/NG diagnostic landscape.

Actionable strategy recommendations for leaders to align R&D, manufacturing flexibility, interoperability, and tailored commercial models to accelerate adoption and reduce exposure to disruption

Industry leaders should prioritize an integrated strategy that aligns technological investments, supply chain resilience, and customer-centric support to capture clinical and commercial opportunities. First, directing R&D toward robust nucleic acid amplification assays and multiplex or dual test formats will meet clinical demand for rapid, accurate and consolidated diagnostics while improving clinical workflow efficiency. Second, strengthening manufacturing flexibility-either through nearshoring, contract manufacturing partnerships, or diversified supplier networks-will mitigate risks tied to trade policy changes and reduce exposure to single-source disruptions.

In addition, companies should enhance instrument and software interoperability to lower barriers to adoption among laboratories and clinics that operate heterogeneous analyzer fleets. Strategic investments in regulatory intelligence and expedited validation pathways will facilitate quicker market access across diverse geographies. Furthermore, building tailored commercial models for academic and research institutes, clinics, diagnostic laboratories and hospitals-each with their own purchasing rhythms-will improve conversion and retention. Finally, pursuing collaborative initiatives with public health programs and clinical networks can reinforce credibility and accelerate uptake, especially for dual testing solutions that offer immediate operational value in screening and treatment workflows.

A rigorous multi-method research framework combining primary stakeholder interviews, technical assay evaluation, and secondary evidence to produce validated, actionable diagnostic insights

The research approach employed a multi-method framework combining primary stakeholder engagement, technical assay review and secondary literature synthesis to deliver robust, actionable insights. Primary research included structured interviews with laboratorians, clinical decision-makers, procurement leaders and regulatory specialists to capture operational constraints, validation expectations and adoption drivers. These engagements were complemented by technical reviews of assay design, instrument specifications and workflow integration to compare performance characteristics and suitability across different use cases.

Secondary research drew on public regulatory documentation, clinical guidelines and peer-reviewed literature to contextualize clinical utility and evidence standards for nucleic acid amplification, hybridization assays and immunoassays. Data synthesis relied on triangulation across sources to validate thematic findings and to surface consistent operational patterns. Quality assurance measures included cross-validation of interview insights, methodical documentation of data provenance, and internal peer review to ensure analytical rigor. This layered methodology ensures that conclusions and recommendations are grounded in real-world practice while remaining sensitive to regulatory and supply chain realities.

Synthesis of diagnostic trends showing how technology convergence, operational resilience, and targeted commercialization must align to sustain adoption and clinical impact

In conclusion, the CT/NG diagnostic landscape is in active transition as molecular techniques, instrument automation and data integration converge to improve clinical pathways and operational efficiency. The rise of dual testing approaches and the increasing feasibility of decentralized testing are reshaping where and how testing occurs, while tariff-driven supply chain pressures emphasize the need for manufacturing flexibility and procurement transparency. Taken together, these themes point to a future in which technological capability must be matched by resilient operations and targeted commercial engagement to achieve sustainable adoption.

For decision-makers, the imperative is clear: align product development and commercialization plans with the practical constraints of end-users, regional regulatory environments and supply chain realities. By doing so, organizations can accelerate clinical impact, strengthen customer relationships and reduce operational risk. The path forward requires coordinated investment across assay innovation, instrument interoperability and supply network design, alongside proactive regulatory planning and tailored go-to-market strategies that reflect the nuanced needs of academic institutions, clinical laboratories, clinics and hospitals.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of point-of-care molecular diagnostics reducing turnaround times in CT/NG testing
• 5.2. Integration of digital health platforms to streamline CT/NG test ordering and patient follow up
• 5.3. Adoption of multiplex syndromic panels combining CT/NG detection with other STI targets to improve diagnostics
• 5.4. Rising demand for at-home self-collection kits for CT/NG screening driven by telemedicine expansion
• 5.5. Impact of antimicrobial resistance surveillance on gonorrhea NAAT assay development and market dynamics
• 5.6. Regulatory shift towards FDA clearance of next generation screening assays for CT/NG detection
• 5.7. Emerging use of CRISPR based diagnostics to enhance sensitivity in chlamydia and gonorrhea testing workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CT/NG Testing Market, by Technology

• 8.1. Culturing Methods
• 8.2. Hybridization Assays
• 8.3. Immunoassays
• 8.4. Nucleic Acid Amplification Tests
  • 8.4.1. Isothermal Amplification
    • 8.4.1.1. Loop Mediated Isothermal Amplification
    • 8.4.1.2. Transcription Mediated Amplification
  • 8.4.2. Polymerase Chain Reaction
    • 8.4.2.1. Nested Polymerase Chain Reaction
    • 8.4.2.2. Real Time Polymerase Chain Reaction

9. CT/NG Testing Market, by Product Type

• 9.1. Consumables And Reagents
  • 9.1.1. Control Materials
  • 9.1.2. Kits
  • 9.1.3. Probes And Primers
• 9.2. Instruments
  • 9.2.1. Automated Systems
  • 9.2.2. Hybridization Analyzers
  • 9.2.3. Polymerase Chain Reaction Instruments
• 9.3. Software And Services

10. CT/NG Testing Market, by End User

• 10.1. Academic And Research Institutes
• 10.2. Clinics
• 10.3. Diagnostic Laboratories
• 10.4. Hospitals

11. CT/NG Testing Market, by Test Type

• 11.1. Chlamydia Tests
• 11.2. Dual Tests
• 11.3. Gonorrhea Tests

12. CT/NG Testing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. CT/NG Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. CT/NG Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Hologic, Inc.
  • 15.3.2. F. Hoffmann-La Roche Ltd.
  • 15.3.3. Abbott Laboratories
  • 15.3.4. Becton, Dickinson and Company
  • 15.3.5. Danaher Corporation
  • 15.3.6. bioMerieux SA
  • 15.3.7. QIAGEN N.V.
  • 15.3.8. Siemens Healthineers AG
  • 15.3.9. Thermo Fisher Scientific Inc.
  • 15.3.10. PerkinElmer, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL CT/NG TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL CT/NG TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. CT/NG TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. CT/NG TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CT/NG TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CT/NG TESTING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 288. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 290. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 291. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 292. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 294. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 295. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 296. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 297. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 300. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 301. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 302. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 303. AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 304. AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 305. AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 306. AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 307. AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 308. AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
• TABLE 309. AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 310. AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 311. AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 312. AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 313. AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2024 (USD MILLION)
• TABLE 314. AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2025-2032 (USD MILLION)
• TABLE 315. AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 316. AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 317. AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 318. AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 319. AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 320. AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 321. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 322. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 323. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 324. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 325. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
• TABLE 326. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
• TABLE 327. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
• TABLE 328. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY ISOT